GROSSPATTERN / FUNDAMENTAL STATE / POINT IN TIME

SXTP · Sep 30, 2023

60 DEGREES PHARMACEUTICALS, INC.. A multidimensional configuration derived from the filing available at this observation—never a composite score or recommendation.

STATE CAPABILITYLEVEL 3[email protected]

Inspectable configuration

State dimensions

Filing0001213900-23-088610General Corporate

Debt relative to revenueRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.debt_to_revenue

293.04% · OPTIONAL · NOT_ENOUGH_HISTORY

Operating cash generationRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.operating_cash_flow + gp.fundamentals.revenue

-7331.94% · OPTIONAL · NOT_ENOUGH_HISTORY

Inventory pressureRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.inventory_revenue_ratio

1168.87% · OPTIONAL · NOT_ENOUGH_HISTORY

Gross marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.gross_margin

-39.09% · CORE · NOT_ENOUGH_HISTORY

Operating marginRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.operating_margin

-2972.89% · CORE · NOT_ENOUGH_HISTORY

R&D intensityRAWCurrent state valid · history insufficient

Evidence method

Ratio · gp.fundamentals.rnd + gp.fundamentals.revenue

515.17% · OPTIONAL · NOT_ENOUGH_HISTORY

SBC intensityRAWCurrent state valid · history insufficient

Evidence method

Level · gp.fundamentals.sbc_revenue_ratio

529.55% · OPTIONAL · NOT_ENOUGH_HISTORY

As-filed lineage

Fundamental state history

Each observation is tied to the filing and facts available at that report date. Amendments remain separate.

History13 statesHistory building

Jun 30, 20230/5 normalizedLevel 3 Sep 30, 20230/7 normalizedLevel 3 Dec 31, 20230/8 normalizedLevel 3 Mar 31, 20240/7 normalizedLevel 3 Jun 30, 20240/8 normalizedLevel 3 Sep 30, 20240/9 normalizedLevel 3 Dec 31, 20240/9 normalizedLevel 3 Mar 31, 20250/9 normalizedLevel 3 Jun 30, 20255/9 normalizedLevel 3 Sep 30, 20257/9 normalizedLevel 3 Dec 31, 20257/9 normalizedLevel 3 Mar 31, 20267/9 normalizedLevel 3 Jun 30, 20269/9 normalizedLevel 3

Period transition

What moved in the state?

Balance Sheet Leverage Increased

Previous: 251.97%
Current: 293.04%
Delta: 41.07%

Inventory Pressure Increased

Previous: 781.96%
Current: 1168.87%
Delta: 386.91%

Margin Increased

Previous: -209.04%
Current: -39.09%
Delta: 169.95%

Profitability Decreased

Previous: -1323.65%
Current: -2972.89%
Delta: -1649.24%

R And D Intensity Increased

Previous: 342.46%
Current: 515.17%
Delta: 172.71%

Self-history only

Previous similar states

Similarity compares compatible valid dimensions from this issuer's own point-in-time history. No market-return claim is attached.

Not enough compatible prior states for a transparent self-history match.

Research Graph

Related governed research

Transitioned To · SXTP Fundamental State →Has State · 60 DEGREES PHARMACEUTICALS, INC. →Transitioned To · SXTP Fundamental State →Transitioned To · SXTP BALANCE_SHEET_LEVERAGE_INCREASED →Transitioned To · SXTP INVENTORY_PRESSURE_INCREASED →Transitioned To · SXTP MARGIN_INCREASED →Transitioned To · SXTP PROFITABILITY_DECREASED →Transitioned To · SXTP R_AND_D_INTENSITY_INCREASED →

Method Percentiles and historical matches use only observations available at each point in time. Missing dimensions remain missing. Public price outcomes and cross-market analogues are deliberately absent.